What the FDA Category 2 Reversal Actually Means (And What It Doesn't)

If you've been following peptide news this spring, you've probably seen headlines claiming the FDA "approved" peptides, "lifted the ban," or "legalized" compounds like BPC-157 and TB-500. Most of those headlines are wrong, or at least sloppy enough to be misleading.

Here's what actually happened, what it changes, and why the research conversation matters more now than it did six months ago.

The actual decision

On April 15, 2026, the FDA announced it would remove twelve bulk peptide substances from its Category 2 list: BPC-157, LL-37, DiHexa, DSIP, Epitalon, injectable GHK-Cu, KPV, PEG-MGF, Melanotan II, MOTS-C, Semax, and TB-500. This followed February's announcement from HHS Secretary Robert F. Kennedy Jr. signaling roughly 14 of the 19 restricted peptides would shift back toward Category 1 status.

The reversal came after legal challenges from compounding pharmacy groups, who argued the FDA placed these peptides on the restricted list without the demonstrated safety signal the statute actually requires. The nominators withdrew their nominations. The FDA followed.

That's the news. Now here's what it means.

What Category 1 actually does

The FDA maintains three categories under its interim policy for substances nominated for use in compounding under Section 503A:

• Category 1 means no significant safety risks have been identified, and the FDA exercises enforcement discretion. Compounding pharmacies can legally prepare these substances for patients with a valid prescription.
• Category 2 means the FDA has identified significant safety risks. Compounding is not permitted.
• Category 3 means there isn't enough data to evaluate. Review is ongoing.

Moving a peptide from Category 2 back to Category 1 does one specific thing: it removes the regulatory barrier that prevented licensed 503A and 503B compounding pharmacies from preparing that substance. A physician can now write a prescription. A licensed pharmacy can now legally compound it.

That is the entire scope of what changed.

What this is not

This is not FDA approval. None of these peptides went through Phase 1, 2, and 3 trials. None of them have an approved indication, an approved dose, or an approved label. The FDA has not declared them safe. The FDA has not declared them effective. The FDA has declared that it does not currently have the safety signal required to prohibit them from being compounded.

That is a regulatory distinction, not a clinical endorsement.

This is also not a legalization event in the sense that consumers can now go buy these compounds for personal use. The pathway that opened is the prescription pathway. A licensed clinician evaluates a patient, decides a compounded peptide is appropriate, and writes a prescription. A licensed pharmacy fills it. That is the framework.

And finally, this is not the end of the regulatory process. The FDA has scheduled Pharmacy Compounding Advisory Committee meetings for July 23-24, 2026, to consider whether seven of these peptides should be formally added to the 503A Bulk Drug Substances List. Additional peptides including GHK-Cu, Melanotan II, Cathelicidin LL-37, Dihexa acetate, and PEG-MGF are scheduled for review by February 2027. PCAC recommendations are non-binding. Formal rulemaking comes after that. None of this is settled.

Why this makes research more important, not less

Here is the part that doesn't get enough attention.

The FDA placed these peptides into Category 2 in the first place largely because of a gap in human clinical data. That gap has not closed. It is the same gap it was in September 2023.

Take BPC-157, probably the most discussed peptide on the list. A 2025 systematic review in the American Journal of Sports Medicine screened 544 articles on BPC-157 for orthopaedic applications and found exactly one clinical study that met inclusion criteria. The other 35 included studies were preclinical animal models. A Phase I trial registered in 2015 (NCT02637284) was never completed and its results were never published. The most cited human data comes from a small Phase II ulcerative colitis trial in Croatia from the early 2000s, and the full data set was never released for independent review.

The same pattern holds across most of the list. Strong preclinical signal, limited human data, and a research base concentrated in a small number of labs. That is not a reason to dismiss these compounds. It is a reason to take the research seriously.

Reclassification doesn't generate new data. It changes who can legally compound the substance. The underlying scientific questions — pharmacokinetics in humans, optimal dosing, drug interactions, long-term safety, mechanism of action in human tissue — are exactly where they were before the announcement.

This is why the work matters. The compounds on this list have generated a decade of compelling preclinical evidence. They have generated real interest from clinicians and researchers. They have not yet generated the kind of rigorous human data that lets the field move from interesting to established. That work has to happen, and it has to happen with integrity.

Where Keystone fits

We are a research-use-only supplier. That hasn't changed. It will not change.

Our products are sold for in-vitro and preclinical laboratory research. They are not for human use, not for veterinary use, and not for therapeutic application. The FDA's category decisions affect the prescription compounding pathway, which is a separate regulatory channel with separate participants. Licensed compounding pharmacies operate under USP 795 and 797 standards, state board of pharmacy oversight, and patient-specific prescriptions. That is not us, and it is not what we do.

What we do is supply researchers with materials that meet documented purity and identity standards so that the research that needs to happen can happen. The reclassification announcement, if anything, raises the bar on that work. More clinicians paying attention means more questions that need answers grounded in actual data. More patient interest means more pressure on the research community to deliver evidence that holds up under review.

We take that seriously. Every product page on this site shows the structure, the sequence, the lot information, and the intended research context. We do not make therapeutic claims. We do not suggest dosing protocols for human use. We do not market to anyone who is not conducting legitimate research, and we will continue refusing orders that don't fit that profile.

The honest summary

The FDA did not approve these peptides. The FDA decided it could not justify keeping them on a list reserved for substances with identified safety risks. Those are different things, and the difference matters.

What opened is a regulated prescription pathway through licensed compounding pharmacies, available to patients working with a licensed clinician. What did not open is a green light for self-administration, online ordering of injectables for personal use, or any claim that these compounds have been validated for human therapeutic use.

The research is what closes that gap. The research is what determines whether these peptides eventually earn formal approval, formal indication labels, and the kind of evidence base that lets clinicians prescribe with confidence. The work our customers do is part of how that happens.

That is the actual story behind the headlines.